Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 46,888 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 46,888 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $4.38, for a total value of $205,369.44. Following the sale, the chief executive officer now directly owns 15,298,896 shares of the company’s stock, valued at approximately $67,009,164.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

David Zaccardelli also recently made the following trade(s):

• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $1,076,533.92.

Verona Pharma Stock Performance

Shares of VRNA stock traded up $0.24 during trading on Tuesday, reaching $38.39. The company had a trading volume of 1,210,037 shares, compared to its average volume of 923,131. The company has a market capitalization of $3.12 billion, a PE ratio of -25.06 and a beta of 0.42. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. The firm’s 50 day simple moving average is $30.84 and its two-hundred day simple moving average is $22.33. Verona Pharma plc has a one year low of $11.39 and a one year high of $39.40.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The company had revenue of $5.62 million for the quarter, compared to analyst estimates of $2.31 million. During the same period in the prior year, the company posted ($0.18) earnings per share. Sell-side analysts forecast that Verona Pharma plc will post -2.07 earnings per share for the current year.

Analyst Ratings Changes

VRNA has been the topic of a number of recent analyst reports. Truist Financial lifted their price objective on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. HC Wainwright increased their price objective on shares of Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday. Canaccord Genuity Group boosted their target price on Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Wells Fargo & Company boosted their price objective on Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Verona Pharma has an average rating of “Buy” and a consensus price target of $43.83.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC bought a new stake in shares of Verona Pharma during the second quarter valued at approximately $29,000. EMC Capital Management bought a new position in shares of Verona Pharma during the second quarter valued at $38,000. GAMMA Investing LLC grew its stake in Verona Pharma by 70.6% during the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock worth $38,000 after buying an additional 553 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Verona Pharma by 25.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after buying an additional 529 shares during the last quarter. Finally, Legato Capital Management LLC bought a new stake in shares of Verona Pharma during the second quarter valued at approximately $154,000. Institutional investors own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.